The purpose of this trial is to examine the short term effects (24 Weeks) of GM1 on
Parkinson's disease (PD) symptoms, as well as the effects of long-term treatment (120 Weeks)
with GM1 on disease progression, and to examine the extent to which GM1 treatment influences
the underlying disease process in PD.
Phase:
Phase 2
Details
Lead Sponsor:
Thomas Jefferson University
Collaborator:
National Institute of Neurological Disorders and Stroke (NINDS)